Given the emerging critical roles of CD47 and CRT in NSCLC adenocarcinomas, in the present study, we assessed whether the EGFR TKI gefitinib modulates their expression in different EGFR-mutated NSCLCs. The gene discussed is CD47; the disease is non-small cell lung carcinoma.